Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines

The technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of the exogenous gene into an intergenic region (IGR) of the viral genome (i.e. Modified Vaccinia Ankara, MVA), where the IGR is flanked by open reading frames of conserved poxvirus genes. Furthermore, the invention relates to plasmids vectors useful to insert the exogenous DNA into the genome of a vaccinia virus. Stability can be further enhanced by incorporating silent mutations that decrease the lengths of homopolynucleotide runs in the foreign gene.

Potential Commercial Applications: Competitive Advantages:
  • Efficient production of vaccinia-vectored vaccines for infectious diseases and other diseases such as cancer
  • Efficient production of therapeutic proteins from vaccinia-vectored exogenous genes
  • Enhancing stability of foreign genes in vaccinia-vectored constructs
  • Increasing efficiency of vaccine production and gene expression

Bernard Moss (NIAID)

Intellectual Property:
US Application No. 13/502,205
US Application No. 61/252,326
PCT Application No. PCT/US2010/052929

Licensing Contact:
John Stansberry , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
Phone: 301-435-5236
Fax: 301-402-0220

OTT Reference No: E-018-2010/0

Updated: 03/01/2010